DE69326234D1 - Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff - Google Patents

Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff

Info

Publication number
DE69326234D1
DE69326234D1 DE69326234T DE69326234T DE69326234D1 DE 69326234 D1 DE69326234 D1 DE 69326234D1 DE 69326234 T DE69326234 T DE 69326234T DE 69326234 T DE69326234 T DE 69326234T DE 69326234 D1 DE69326234 D1 DE 69326234D1
Authority
DE
Germany
Prior art keywords
active substance
gel matrix
matrix containing
medicine system
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69326234T
Other languages
English (en)
Other versions
DE69326234T2 (de
Inventor
Margaret Joan Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
De Montfort University
Original Assignee
De Montfort University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Montfort University filed Critical De Montfort University
Application granted granted Critical
Publication of DE69326234D1 publication Critical patent/DE69326234D1/de
Publication of DE69326234T2 publication Critical patent/DE69326234T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69326234T 1992-01-10 1993-01-08 Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff Expired - Lifetime DE69326234T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929200638A GB9200638D0 (en) 1992-01-10 1992-01-10 Drug system
PCT/GB1993/000034 WO1993013803A1 (en) 1992-01-10 1993-01-08 Drug system

Publications (2)

Publication Number Publication Date
DE69326234D1 true DE69326234D1 (de) 1999-10-07
DE69326234T2 DE69326234T2 (de) 1999-12-30

Family

ID=10708507

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326234T Expired - Lifetime DE69326234T2 (de) 1992-01-10 1993-01-08 Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff

Country Status (11)

Country Link
US (2) US5830506A (de)
EP (1) EP0626862B1 (de)
JP (1) JP4025363B2 (de)
AT (1) ATE183927T1 (de)
AU (1) AU3263093A (de)
DE (1) DE69326234T2 (de)
DK (1) DK0626862T3 (de)
ES (1) ES2135458T3 (de)
GB (1) GB9200638D0 (de)
GR (1) GR3031479T3 (de)
WO (1) WO1993013803A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii
GB9805896D0 (en) 1998-03-20 1998-05-13 Eglise David Remote analysis system
WO2001016575A1 (en) * 1999-08-27 2001-03-08 M-Biotech, Inc. Glucose biosensor
WO2001081890A2 (en) * 2000-04-22 2001-11-01 M-Biotech, Inc. Hydrogel biosensor and biosensor-based health alarm system
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
WO2003015704A2 (en) 2001-08-17 2003-02-27 University Of Pittsburgh Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
US20080279936A1 (en) * 2001-10-10 2008-11-13 The University Of Pittsburgh Estradiol metabolites for reduction of endothelin production
US20090118605A1 (en) * 2002-08-30 2009-05-07 Northwestern University Surface-enhanced raman nanobiosensor
WO2004056311A2 (en) 2002-12-17 2004-07-08 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
US20060194775A1 (en) * 2003-02-20 2006-08-31 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
WO2004073643A2 (en) * 2003-02-20 2004-09-02 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
US7806856B2 (en) * 2005-04-22 2010-10-05 Accessclosure, Inc. Apparatus and method for temporary hemostasis
WO2007047997A2 (en) * 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
ES2791683T3 (es) 2009-01-28 2020-11-05 Smartcells Inc Sistemas a base de conjugados para la administración controlada de fármacos
EP2391217A4 (de) 2009-01-28 2015-05-20 Smartcells Inc Synthetische konjugate und ihre verwendung
US8906850B2 (en) 2009-01-28 2014-12-09 Smartcells, Inc. Crystalline insulin-conjugates
US8846103B2 (en) 2009-01-28 2014-09-30 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2805902A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
EP2598527A4 (de) 2010-07-28 2014-01-08 Smartcells Inc Rekombinant exprimierte insulinpolypeptide und anwendungen davon
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
GB201314640D0 (en) 2013-08-15 2013-10-02 Univ Montfort Matrix gel
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US11041009B2 (en) 2017-03-23 2021-06-22 Merck Sharp & Dohme Corp. Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
CN114432243B (zh) * 2022-01-20 2023-08-29 华南师范大学 一种响应pH和葡萄糖的纳米载体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US6159502A (en) * 1991-04-02 2000-12-12 Biotech Australia Pty Ltd Oral delivery systems for microparticles
GB9200638D0 (en) 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii

Also Published As

Publication number Publication date
EP0626862A1 (de) 1994-12-07
ATE183927T1 (de) 1999-09-15
US5830506A (en) 1998-11-03
DK0626862T3 (da) 1999-12-13
US7063863B2 (en) 2006-06-20
WO1993013803A1 (en) 1993-07-22
DE69326234T2 (de) 1999-12-30
US20020168409A1 (en) 2002-11-14
JPH07507268A (ja) 1995-08-10
GB9200638D0 (en) 1992-03-11
EP0626862B1 (de) 1999-09-01
AU3263093A (en) 1993-08-03
GR3031479T3 (en) 2000-01-31
ES2135458T3 (es) 1999-11-01
JP4025363B2 (ja) 2007-12-19

Similar Documents

Publication Publication Date Title
DE69326234D1 (de) Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff
AU628674B2 (en) Polymer complexes of a sugar response type
US5902607A (en) Reversible cross-linked gel
Draget et al. Alginate based new materials
Sun et al. Design and synthesis of biotin chain-terminated glycopolymers for surface glycoengineering
CN108676178B (zh) 改性多糖水凝胶的制备方法及制备的改性多糖水凝胶
Crescenzi et al. Novel hydrogels via click chemistry: synthesis and potential biomedical applications
US5603956A (en) Cross-linked enzymatically controlled drug release
GB1283857A (en) Size for glass fibres
Liao et al. Temperature/pH dual sensitive Hericium erinaceus residue carboxymethyl chitin/poly (N-isopropyl acrylamide) sequential IPN hydrogels
JP3647859B2 (ja) 酵素的に制御された薬剤放出のための架橋されたポリヒドロキシ材料
Albin et al. Glucose-sensitive membranes for controlled release of insulin
CN1830420A (zh) 一种可注射型pH敏感壳聚糖季铵盐水凝胶及其制备方法
Yang et al. Recent advances in smart hydrogels prepared by ionizing radiation technology for biomedical applications
NO131417B (de)
He et al. In Vitro Synthesis of Branchless Linear (1→ 6)-α-d-Glucan by Glucosyltransferase K: Mechanical and Swelling Properties of Its Hydrogels Crosslinked with Diglycidyl Ethers
US4379038A (en) Process for preparing a physiologically active substance controlled release composite composition
Madivoli Polysaccharide based hydrogels in drug delivery systems, wound healing, and agriculture
Baghel et al. Carboxymethylated gums and derivatization: Strategies and significance in drug delivery and tissue engineering
CN108329491A (zh) 一种稳定温敏型高分子水凝胶
De Moor et al. Long-term structural changes in pH-sensitive hydrogels
US5215752A (en) Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
KR920002167A (ko) 자가 방출 조절형 인슐린제형
SE7900738L (sv) Farmaceutiskt medel
Shiino et al. Controlled release of insulin from boronic acid gel under physiological conditions

Legal Events

Date Code Title Description
8364 No opposition during term of opposition